BCR and prostate cancer: Clinical follow‐up data in the validation cohort, with a median of 15 years (range: 0.8–22 years), showed that 86 patients (46.5%) had a BCR, 25 patients (13.5%) had an MR and 16 patients (8.6%) died of prostate cancer.